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The paper presents the findings of our own studies on the evaluation of the effect of anthracycline-induced oxidative 
stress on the level of N-acetylneuraminic acid and the state of the processes of free radical oxidation and antioxidant protection in 
the mucous membrane of rat small and large intestines depending on the presence of nonalcoholic steatohepatitis. 30 mature 
outbred albino rats were involved into studies. The cumulative dose of doxorubicin was 15 mg/kg. In the mucous membrane of the 
small intestine of rats with nonalcoholic steatohepatitis, administration of doxorubicin resulted in less pronounced oxidative 
damage and 1.2-fold decrease in N-acetylneuraminic acid concentration compared to rats without nonalcoholic steatohepatitis. It 
has been proved that administration of doxorubicin led to the development of doxorubicin-induced oxidative stress in the intestinal 
mucosa of rats with more severe lesions of the small intestine, regardless of the presence of nonalcoholic steatohepatitis.  
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Р.І. Скрипник, Г.С. Маслова  
ВПЛИВ ДОКСОРУБІЦИН-ІНДУКОВАНОГО ОКСИДАТИВНОГО СТРЕСУ  
НА РЕЗИСТЕНТНІСТЬ СЛИЗОВОЇ ОБОЛОНКИ КИШКІВНИКА 
 
У статті наведені результати власних досліджень по оцінці впливу антрациклін-індукованого оксидативного стресу 
на рівень N-ацетилнейрамінової кислоти та стан процесів вільно-радикального окиснення та антиоксидантного захисту у 
слизовій оболонці тонкої і товстої кишок щурів залежно від наявності неалкогольного стеатогепатиту. Дослідження проведені 
на 30 білих нелінійних статевозрілих щурах. Кумулятивна доза доксорубіцину склала 15 мг/кг. У слизовій тонкої кишки щурів 
із неалкогольним стеатогепатитом введення доксорубіцину приводило до менш вираженого оксидативного ураження та 
зменшення концентрації N-ацетилнейрамінової кислоти у 1,2 раза порівняно з щурами без неалкогольного стеатогепатиту. 
Доведено, що введення доксорубіцину призводило до розвитку доксорубіцин-індукованого оксидативного стресу в слизовій 
кишківника щурів з більш тяжким ураженням тонкої кишки незалежно від наявності неалкогольного стеатогепатиту.  
Ключові слова: доксорубіцин, оксидативний стрес, перекисне окиснення ліпідів, антиоксидантна система, 
резистентність слизової оболонки, кишківник. 
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Currently, the evidence has been given that a large number of chemotherapeutic drugs can lead to the 
development of inflammation and dysfunction of the entire gastrointestinal tract (GIT). Thus, chemotherapy-
induced mucositis (CHIM) is one of the most common complications of cytostatic therapy. Clinical 
manifestations of CHIM can be painful ulcerations in the oral cavity, nausea, vomiting, abdominal pain, 
diarrhea, inflammation and origination of erosions and ulcers of the GIT mucous membrane (MM) [10]. It 
has been reported that the toxic effects of doxorubicin on GIT led to vomiting and development of mucositis 
during the first 5-10 days of chemotherapy (CHT). In most patients, GIT MM was restored within the next 
10 days of treatment, though, in patients with severe reactions to administration of doxorubicin, ulceration 
and intestinal necrosis was observed with subsequent development of infectious complications with possible 
fatal consequences [15]. Furthermore, clinically significant consequences of CHIM may be a reduction or 
complete cessation of patients’ intake of food and oral medications, resulting in the development of anorexic-
induced atrophy of GIT MM. The need for intake of oral chemotherapeutic drugs increases the risk for 
systemic infections. The side effects related to GIT can lead to reduction in the maximum tolerated dose for 
many chemotherapeutic agents, resulting in lowering of the effectiveness of treatment. Evaluation of the 
degree of MM damage and GIT dysfunction caused by chemotherapeutic drugs is also challenging. Thus, 
generally, examinations of patients are limited to the evaluation of the oral cavity, general health state and the 
use of indirect indices of the functioning of the GIT, namely, hydrogen breath tests, biochemical blood test 
and microbiological studies [10]. The state of GIT MM resistance and the degree of its damage under the 
effect of cytostatic drugs can be assessed by the level of N-acetylneuraminic acid (NANA) [3]. 
Doxorubicin is anthracycline antibiotic that is one of the most effective cytotoxic drugs in the 
treatment of both solid and hematological malignancies, including Hodgkin’s lymphoma and non-
Hodgkin’s lymphomas, acute and chronic leukemia. Currently, two main antitumor mechanisms of action 
of doxorubicin have been established. One of them is related to the property of doxorubicin to cause 
degradation of topoisomerase II, disrupting the process of DNA repair and causing its degradation [8]. The 
second mechanism of action of the drug is associated with the induction of oxidative stress, which affects 
both the cell membrane, cell DNA and numerous proteins, namely, NADH dehydrogenase, nitric oxide 
synthase, xanthine oxidase, glutathione peroxidase, catalase and superoxide dismutase [15]. Thus, 
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NADPH-cytochrome P-450 converts doxorubicin to a semihinone radical, which in turn initiates the 
production of superoxide anion and hydroxyl radicals, which cause lipid peroxidation [12]. 
The probability of developing CHT complications is influenced by the presence of patient’s 
comorbidities. From this point of view, the study of the role of nonalcoholic steatohepatitis (NASH) in the 
development of cytostatic-induced lesions of the GIT is of particular importance. Oxidative stress is given an 
important role in the pathophysiological mechanisms of NASH development. Thus, according to numerous 
clinical observations and experimental studies in animal models, a strong relationship between the degree of 
oxidative damage and the severity of NASH has been shown [6, 8]. In view of the above, the study the course 
of oxidative lesions of the intestine with the use of doxorubicin in the presence of NASH is rational. 
The purpose of the study was to establish the effect of anthracycline-induced oxidative stress on 
the level of N-acetylneuraminic acid, the state of the processes of free radical oxidation (FRO) and 
antioxidant protection in mucous membrane of the small and large intestines of rats depending on the 
presence of nonalcoholic steatohepatitis. 
Materials and methods. Mature outbred albino rats (n=30; male rats=15 (50 %); female rats=15 
(50 %)) weighted 160-220 g were involved into the study. The experiment was performed in two stages. 
At the first stage a group of animals (n=10; 5 males and 5 females) were exposed to simulated NASH 
during 63 days, induced by a fast-food diet. The ration per one animal for NASH modeling included 
combination fodder-concentrate granulated (0.04 kg), 72.5 % dairy butter (0.01 kg), refined sunflower oil 
(0.01 kg), palm oil (0.01 kg) and 4 % aqueous fructose solution as the sole source of liquid. From day 1 to 
day 63 of the stage I of the experiment, another rats (n=20; 10 males and 10 females) received a regular 
rations of vivarium, containing combination fodder-concentrate granulated (0.04 kg), low-fat cheese 
(0.006 kg), carrots (0.02 kg), cabbage (0.015 kg) per one animal. 
At the second stage of the experiment the modeling of doxorubicin-induced liver damage was 
carried out for three days (from day 64 to day 66), according to which the rats were assigned into groups: 
Group І (n=10; 5 males and 5 females) rats received a regular rations of vivarium from day1 to day 
63. Subsequently, from day 64 to day 66 they were administered with 5mg/kg/day doxorubicin 
intraperitoneally (the cumulative doze of 15 mg/kg). 
Group ІI (n=10; 5 males and 5 females) rats with overweight were exposed to modeled NASH 
from day1 to day 63. Subsequently, from day 64 to day 66 they were administered with doxorubicin similar 
to Group I. 
Group ІІІ (n=10; 5 males and 5 females) rats received a regular rations of vivarium from day1 to 
day 63. Subsequently, from day 64 to day 66 they were administered with 0.9 % sodium chloride solution 
intraperitoneally at a dose of 1 ml. 
The rats were sacrificed under thiopental anesthesia on day 67 of the observation. 
Dissection of the animals’ anterior abdominal wall was performed. The small and large intestines 
were taken out and cut lengthwise, subsequently washed with 0.9% sodium chloride solution and MM was 
separated with a scalpel. Then the MM of the small and large intestines was homogenized in 0.9% sodium 
chloride solution in a ratio of 1: 5 at a speed of 3000 rpm in a homogenizer. 
In the homogenate of MM of the small and large intestines, the state of free radical oxidation (FRO) 
processes was determined by the concentration of substances that form a trimethine complex (TBA-
reactants) with 2-thiobarbituric acid [4] and the antioxidant system (AOS) by catalase activity [2]. 
Resistance of the mucous barrier of the small and large intestines was determined by the concentration of 
NANA in the mucosal homogenate [1]. 
Statistical processing of the resulting data was performed using the GraphPad Prism version 5.00 
statistical program (GraphPad Software, Inc., San Diego, CA, USA) to perform parametric and 
nonparametric statistical analysis. With the normal distribution of data, the results were presented in the 
form of arithmetic means (M) and their error (m). Significance of the differences was calculated using the 
Student’s t-test. Paired nonparametric methods of Wilcoxon and Mann-Whitney rank tests were used in the 
distribution that differs from the normal one. The relationship between the studied indices was evaluated 
using Spearman’s correlation analysis. Differences at p<0.05 were considered statistically significant. The 
research was carried out in compliance with the Declaration of Helsinki principles. 
Results of the study and their discussion. In rats of Group I, administration of doxorubicin in a 
cumulative dose of 15 mg/kg led to activation of the FRO processes, which was characterized by 2.1 times 
(p=0.002) increased amount of TBA reactants in the small intestine homogenate and a decrease in catalase 
activity by 3.4 times compared to the control group (p=0.002) (table 1). Consequently, administration of 
doxorubicin in rats leads to imbalance between the FRO production and the activity of AOS enzymes in 
the MM of the small intestine, resulting in increased levels of free radicals, which is a prerequisite for 
oxidative damage to enterocytes. 
Thus, oxidative stress in rats of Group I caused an increase in the level of NANA in the MM of the 
small intestine by 1.6 times compared to the control group (p=0.002) (table 1), which indicates 
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doxorubicin-induced  activation of free radical damage in its MM. It can be assumed that doxorubicin leads 
to the development of oxidative stress, which is accompanied by both increased production of free radicals 
and antioxidant protection disorder of the small intestine. 
Table 1 
The indices of free radical oxidation and NANA content in the small intestinal mucosa, M±m 
Note: in this table and thereafter the significant difference between: p1 (p<0.05) – indices of subgroups I and II; p2 (p<0.05) – 
indices of subgroups I and III; p3 (p<0.05) – indices of subgroups II and III. 
 
In Group II rats with simulated NASH, administration of doxorubicin was accompanied by a 1.4-
fold increase in the concentration of TBA reactants in the small intestine homogenate (p=0.0059) with a 
simultaneous 5.2-fold decrease in catalase activity compared to the controls (p=0.002). Oxidative damage 
of MM of the small intestine in Group II rats with NASH and overweight caused 1.4-fold increase in 
concentration of NANA in the small intestinal mucosa compared to the control group (p=0.002) (table 1).  
Generally, in Group II rats with overweight, the degree of oxidative damage was characterized by 
a smaller increase in the indices compared to Group I. Thus, the level of TBA reactants and catalase activity 
in the homogenate of the small intestine in rats of Group II was lower by 1.5 (p=0.0059) and 1.4 times 
(p=0.002), respectively, compared to Group I. Moreover, the NANA concentration in the small intestinal 
mucosa of rats of Group II was by1.2 times (p=0.00137) lower compared to Group I, which indicates a less 
pronounced lesion of the mucous membrane (table 1).  
In Group I rats, no significant changes in catalase activity and the amount of TBA reactants in the 
homogenate of the large intestine have been found compared to the control group. In Group II rats with 
overweight, the level of TBA reactants was by 1.8 times (p=0.0059) higher than in the control group and 
no significant changes in catalase activity was noted (table 2). The increased amount of TBA reactants is 
primarily a consequence of doxorubicin-induced oxidative stress, which leads to damage to enterocytes of 
the large intestine and a decrease in its resistance, as evidenced by an increase in NANA levels in MM of 
the large intestine in Group I rats by 1.7 times (p=0.002) in the absence of significant changes in rats of 
Group II, compared to the controls.  
In overweight rats, the level of TBA reactants was by 1.6 times (p=0.0059) higher than in rats of 
Group I in the absence of significant changes in catalase activity (table 2).  
Table 2  
The indices of free radical oxidation and NANA content in the large intestinal mucosa, M±m 
 
The findings indicate a higher level of oxidative stress in the mucous membrane of the large 
intestine in overweight rats compared to Group I. Admittedly, no more severe damage to MM has been 
noted, as evidenced by a 1.4-fold increase (p=0.0273) in the concentration of NANA in the mucous 
membrane of rats of Group I, compared to Group II. 
Therefore, generally, administration of doxorubicin led to the development of doxorubicin-induced 
oxidative stress in the mucous membrane of the small and large intestine of rats of both groups. 
A characteristic feature of doxorubicin-induced intestinal lesions, regardless of the rats’ body weight, was 
more severe damage to MM of the small intestine, which may be associated with more pronounced metabolic 
activity of proximal intestinal enterocytes. In addition, overweight rats had less pronounced intestinal lesions 
Indices 
Groups of the experimental animals 
І (n=10) ІІ (n=10) ІІІ (n=10) 
Catalase,  μmol/g 5.005±0.1839 
95% CI 4.589-5.421 
3.315±0.1561 
95% CI  2.962-3.668 
17.42±0.2789 
95% CI 16.79-18.05 
р р1=0.002 р2=0,002 р3=0,002 
TBA reactants,  nkat/g 17.30±0.9149 
95% CI 15.23-19.37 
12.07±1.344 
95% CI  9.029-15.11 
8.211±0.2951 
95% CI 7.544-8.879 
р р1=0.0059 р2=0.002 р3=0.0059 
NANA, μmol/g 52.41±2.978 
95% CI 45.67-59.14 
42.80± 1.776 
95% CI 38.78-46.82 
31.64±0.5672 
95% CI 30.35-32.92 
р р1=0.0137 р2=0.002 р3=0.002 
Indices Groups of experimental animals 
І (n=10) ІІ (n=10) ІІІ (n=10) 
Catalase , μmol/g 4.191±0.4483 
95% CI 3.177-5.205 
3.644±0.2521 
95% CI 3.074-4.215 
3.370±0.2395 
95% CI 2.828-3.912 
р р1>0.05 р2>0.05 р3 >0.05 
TBA reactants,  nkat/g 15.87±0.5586 
95% CI 14.60-17.13 
26.16±2.116 
95% CI 21.37-30.95 
14.66±0.6746 
95% CI 13.14-16.19 
р р1=0.0059 р2>0.05 р3=0,0059 
NANA, μmol/g 5.857±0.478 
95% CI 4.776-6.938 
4.104±0.7153 
95% CI 2.486 -5.722 
3.445±0.5147 
95% CI 2.280-4.609 
р р1=0.0273 р2=0.002 р3>0.05 
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compared to the rat with normal body weight. The findings can be assigned to the so-called “obesity paradox”. 
Currently, it is hypothesized that excessive amount of the adipose tissue, which is usually roughly expressed 
in the body mass index, is associated with a lower survival rate in oncology treatment. However, some studies 
have proved that overweight and early obesity in patients was associated with better survival rates than in 
patients with normal body weight. This phenomenon, which characterizes the differences in the impact of 
obesity on the survival and treatment outcomes of patients, is called the “obesity paradox”. Thus, the “obesity 
paradox” has been described in the treatment of numerous forms of oncology, namely, colorectal cancer [13], 
kidney cancer [7], in the treatment of acute myeloid leukemia in elderly patients [5], and in patients with 
lymphoma who underwent autologous hematopoietic stem cell transplantation [11]. 
Sinicrope FA, Foster NR [14] in the study of the prognostic value of body mass index in 25.291 patients 
with colon cancer of stage II and III who took 5-fluorouracil as adjuvant therapy, proved that the survival rates 
of patients with body mass index 25.0-34.9 kg/m2 were better compared to patients who had a normal weight. 
The explanation for the higher survival rate of overweight patients can be the so-called hibernation 
hypothesis, which considers the adipose tissue as an energy depot that during stress, which is actually 
anticancer therapy, may give an advantage in survival. This theory is similar to the hibernation theory in 
evolutionary biology, in which animals set aside energy reserves in anticipation of difficult times ahead [9]. 
 
Conclusions  
1. In rats without NASH, administration of doxorubicin at a cumulative dose of 15 mg/kg leads to 
oxidative damage to the MM of the small intestine, which was characterized by an increase in the amount 
of TBA reactants by 2.1 times (p=0.002), a decrease in catalase activity by 3.4 times (p=0.002) and an 
increase in the level of NANA by 1.6 times (p=0.002) in its homogenate compared to the control group.   
2. In rats with NASH and overweight, administration of doxorubicin at a cumulative dose of 15 
mg/kg leads to activation of free radical lesions of the MM of the small intestine, which was characterized 
by a 1.4-fold increase in the concentration of TBA reactants (p=0.0059) concomitant with decreased 
catalase activity – by 5.2 times (p=0.002), and an increase in NANA concentration – by 1.4 times compared 
to the control group (p=0.002). 
3. In MM of the small intestine of rats with NASH, administration  of doxorubicin caused less 
pronounced oxidative damage compared to the rats with normal body weight, as evidenced by lowering 
the level of TBA reactants by 1.5 times (p=0.0059), catalase activity – by 1.4 times (p=0.002) and NANA 
concentration – by 1.2 times (p=0.00137). 
4. In MM of the large intestine of rats with NASH and overweight, administration of doxorubicin 
caused a more pronounced activation of FRO, as evidenced by a 1.6-fold higher (p=0.0059) level of TBA 
reactants compared to rats with normal weight and by 1.8 times higher (p=0.0059) compared to the control 
group. Admittedly, no more severe damage to MM was noted, as evidenced by a 1.4-fold increased 
(p=0.0273) concentration of NANA in normal weight rats compared to overweight rats. 
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